This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ferrario, C. M Search for Related Content PubMed PubMed Citation Articles by Ferrario, C. M Social Bookmarking                         What's this?

Role of Angiotensin II in Cardiovascular Disease — Therapeutic Implications of More Than a Century of Research

The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA, cferrari{at}wfubmc.edu

More than a century of research on the renin-angiotensin system (RAS) has uncovered the widespread involvement of angiotensin II (Ang II) in the pathophysiology of cardiovascular diseases. A number of outcomes-based mega trials utilising hard clinical endpoints have revealed beneficial effects of angiotensin receptor antagonists (AIIAs/ARBs) in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction (MI). The results of these studies not only emphasise the importance of Ang II in the pathophysiology of these diseases but have provided the basis for an evidence-based approach for the use of AIIAs in clinical practice. It is hoped that the next 100 years of research into the RAS will uncover hitherto unimaginable therapeutic opportunities.

Key Words: Hypertension • Cardiovascular disease • Diabetes mellitus • Angiotensin II antagonists • ACE inhibitors • Stroke • Heart failure • Post myocardial infarction • Diabetic nephropathy

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1, 3-14 (2006)
DOI: 10.3317/jraas.2006.003


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. R.M. Gomes, A. A. Lara, P. W.M. Almeida, D. Guimaraes, R. R. Resende, M. J. Campagnole-Santos, M. Bader, R. A.S. Santos, and S. Guatimosim Angiotensin-(1-7) Prevents Cardiomyocyte Pathological Remodeling Through a Nitric Oxide/Guanosine 3',5'-Cyclic Monophosphate-Dependent Pathway Hypertension, January 1, 2010; 55(1): 153 - 160. [Abstract] [Full Text] [PDF]

				Q. Tian, R. Miyazaki, T. Ichiki, I. Imayama, K. Inanaga, H. Ohtsubo, K. Yano, K. Takeda, and K. Sunagawa Inhibition of Tumor Necrosis Factor-{alpha}-Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-{gamma} With Nuclear Factor {kappa}B and CCAAT/Enhancer-Binding Protein-{beta} Hypertension, May 1, 2009; 53(5): 798 - 804. [Abstract] [Full Text] [PDF]

				J. W Wright and J. W Harding The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease Journal of Renin-Angiotensin-Aldosterone System, December 1, 2008; 9(4): 226 - 237. [Abstract] [PDF]

				C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF]

				D. W. Wray, S. K. Nishiyama, R. A. Harris, and R. S. Richardson Angiotensin II in the Elderly: Impact of Angiotensin II Type 1 Receptor Sensitivity on Peripheral Hemodynamics Hypertension, June 1, 2008; 51(6): 1611 - 1616. [Abstract] [Full Text] [PDF]

				J. V. C. Felix and L. C. Michelini Training-Induced Pressure Fall in Spontaneously Hypertensive Rats Is Associated With Reduced Angiotensinogen mRNA Expression Within the Nucleus Tractus Solitarii Hypertension, October 1, 2007; 50(4): 780 - 785. [Abstract] [Full Text] [PDF]